Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (836)	10/12/1998 8:35:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 887

John, The referenced press release gives an explanation biz.yahoo.com In essence, the FDA turned them down for the NM from solid tumor indication. But, they have now left the door open for approval for the NM from lymphoma indication. IMHO: approval will be forthcoming. But, remember, I predicted that DepoCyt would be approved for solid tumors. NM from lymphomas is a very small subject population. Even if DepoCyt is used off label, I wouldn't expect a substantial amount of revenue generated. But, the FDA approval would be a major landmark in that it would immediately legitimize the DepoFoam platform. That could have a major impact on the stock price. John de C